Discovery of HTL6641, a dual orexin receptor antagonist with differentiated pharmacodynamic properties

A novel series of potent, selective, and orally efficacious dual antagonists of the orexin receptors has been investigated, resulting in the identification of lead compound 27 (HTL6641). Comprehensive data for 27 are presented, including in vivo PK parameters, confirmation of receptor occupancy thro...

Full description

Saved in:
Bibliographic Details
Published in:MedChemComm 2015-05, Vol.6 (5), p.947-955
Main Authors: Christopher, John A., Aves, Sarah J., Brown, Jason, Errey, James C., Klair, Suki S., Langmead, Christopher J., Mace, Oliver J., Mould, Richard, Patel, Jayesh C., Tehan, Benjamin G., Zhukov, Andrei, Marshall, Fiona H., Congreve, Miles
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A novel series of potent, selective, and orally efficacious dual antagonists of the orexin receptors has been investigated, resulting in the identification of lead compound 27 (HTL6641). Comprehensive data for 27 are presented, including in vivo PK parameters, confirmation of receptor occupancy through ex vivo binding and efficacy in a rat sleep model. A key feature of the series is a short dissociation half-life, measured by surface plasmon resonance (SPR) using stabilized receptors, and confirmed by radioligand-binding experiments. Based on a consideration of the requirements for a potential treatment for insomnia, compound 27 was identified as having the best balance of properties from the chemical series.
ISSN:2040-2503
2040-2511
DOI:10.1039/C5MD00027K